Services - 373604-2020

07/08/2020    S152

United Kingdom-London: Medical software development services

2020/S 152-373604

Prior information notice

This notice aims at reducing time limits for receipt of tenders

Services

Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Official name: MHRA Buyer Organisation
Postal address: 10 South Colonnade
Town: London
NUTS code: UKI LONDON
Postal code: E14 4PU
Country: United Kingdom
E-mail: purchasing@mhra.gov.uk
Internet address(es):
Main address: www.mhra.gov.uk
Address of the buyer profile: https://mhra.bravosolution.co.uk
I.2)Information about joint procurement
The contract is awarded by a central purchasing body
I.3)Communication
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: https://mhra.bravosolution.co.uk
Tenders or requests to participate must be submitted to the abovementioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at: https://mhra.bravosolution.co.uk
I.4)Type of the contracting authority
National or federal agency/office
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Vigilance Signal Detection and Management Technology Systems and Associated Services

II.1.2)Main CPV code
72212180 Medical software development services
II.1.3)Type of contract
Services
II.1.4)Short description:

The SafetyConnect programme is a technology-enabled strategic business change programme. It aims to significantly enhance the UK’s vigilance capability and revolutionise the way it shares and uses information for the greatest public health impact. The programme will achieve this by investing in increased technological capabilities that can better analyse and respond to adverse drug reactions and incidents related to medical devices and blood reported by patients, the healthcare community and manufacturers.

This is an integral part of the Agency’s overall ambition and provides a unique opportunity to transform how the Agency monitors and acts on safety insights across the full product lifecycle, through joined up safety vigilance, reporting and information.

The MHRA are seeking to procure new systems and associated services to replace its existing specialist signal detection, case management and analytics systems used in its pharmacovigilance and medial product vigilance activities.

II.1.5)Estimated total value
Value excluding VAT: 5 000 000.00 GBP
II.1.6)Information about lots
This contract is divided into lots: yes
Tenders may be submitted for all lots
Maximum number of lots that may be awarded to one tenderer: 2
II.2)Description
II.2.1)Title:
Lot No: Lot 1 - Specialist technology solutions, services and implementation activities
II.2.2)Additional CPV code(s)
48000000 Software package and information systems
72000000 IT services: consulting, software development, Internet and support
II.2.3)Place of performance
NUTS code: UK UNITED KINGDOM
II.2.4)Description of the procurement:

Deliver the core capabilities of signal detection and management, integrated case management and vigilance analytics — the MHRA require solution(s) and associated services to provide a comprehensive capability to manage signal detection, vigilance caseloads, and analytics across all medicines and healthcare products. This includes migration from current systems. The MHRA is also looking to automate (where feasible) signal detection, safety updates and distribution of reporting to speed-up analytics and knowledge sharing.

II.2.5)Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information
II.2)Description
II.2.1)Title:
Lot No: Lot 2 - Pharmacovigilance artificial intelligence and natural language processing capability
II.2.2)Additional CPV code(s)
48000000 Software package and information systems
72000000 IT services: consulting, software development, Internet and support
II.2.3)Place of performance
NUTS code: UK UNITED KINGDOM
II.2.4)Description of the procurement:

The MHRA have a need for a proven machine learning and natural language processing solution to assist in the receipt and processing of specific adverse drug reactions. This solution is required to replace an interim solution to ensure that all additional case details are automatically detected from reaction text.

II.2.5)Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information
II.3)Estimated date of publication of contract notice:
14/09/2020

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation
III.1.2)Economic and financial standing
Selection criteria as stated in the procurement documents
III.1.3)Technical and professional ability
Selection criteria as stated in the procurement documents

Section IV: Procedure

IV.1)Description
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.5)Scheduled date for start of award procedures:
07/12/2020

Section VI: Complementary information

VI.2)Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Official name: Medicines and Healthcare products Regulatory Agency
Town: London
Country: United Kingdom
VI.5)Date of dispatch of this notice:
04/08/2020